Loading stock data…
VCEL
$35.57+0.84 (+2.42%)
Market ClosedLast close May 1
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vericel Corporation in the Healthcare sector is trading at $35.57. The stock is currently 23% below its 52-week high of $45.97, remaining 0.3% below its 200-day moving average. Technical signals show neutral RSI of 54 and bullish MACD crossover, explaining why VCEL maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$35.57
Potential Downside
82.5%
Whystock Fair Value$6.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North Ame...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.71B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
105.16
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.00%
Volume
Today's trading volume
342,402
Recent News
Vericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC Auditor
Vericel (NASDAQ:VCEL) held its 2026 annual meeting of shareholders on April 29 in a virtual format, with Chairman Dr. Robert Zerbe presiding. Zerbe said the meeting was conducted pursuant to Michigan law, the company’s bylaws, and the notice distributed to shareholders. Sean Flynn, Vericel’s corpora
Exploring Three High Growth Tech Stocks In The US Market
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth expectations, identifying high growth tech stocks that align with these trends can be crucial for investors seeking opportunities in a dynamic sector.
What Makes Vericel Corporation (VCEL) an Investment Bet?
Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Small Cap Fund”. A copy of the letter can be downloaded here. The fourth quarter was challenging for the fund and continued to underperform its benchmark, the Russell 2000 Index. The fund (Class I) returned -0.4%, lagging the benchmark’s 2.2% return. Sector allocation […]
Will FDA Approval of Burlington MACI Manufacturing Shift Vericel's (VCEL) Long-Term Growth Narrative
In early March 2026, Vericel Corporation reported that the FDA approved commercial manufacturing of its knee cartilage repair therapy MACI at the company’s Burlington, Massachusetts cell therapy facility, allowing production to begin there in the second quarter of 2026. This manufacturing approval not only expands MACI capacity and strengthens Vericel’s supply chain, but also underpins the company’s ability to pursue international commercialization of its autologous cell therapy...
FDA MACI Approval Tests Vericel’s Capacity Plans And Growth Story
Vericel received FDA approval for commercial manufacturing of MACI at its new Burlington facility. The approval allows expanded production capacity for the company’s cartilage repair therapy. The new site is expected to support Vericel’s plans for potential MACI commercialization outside the U.S. For investors watching Vericel, ticker NasdaqGM:VCEL, this FDA decision marks an important operational shift as the company looks to support demand for MACI. The stock last closed at $34.12, with a...